Fibrocell acquires rights from UCLA; seeks a lead on adult mesenchymal stem cells from dermal skin cells
This article was originally published in Scrip
Executive Summary
Fibrocell Science, a US regenerative cell therapy firm, has been keeping quite busy since US launch in October 2011 of its autologous aesthetic cell therapy laViv (azficel-T), which is indicated to improve smile lines and uses a patient's own collagen-making skin cells, or fibroblasts. The company is venturing into new areas – the most exciting of which is adult mesenchymal stem cells which are derived from dermal skin cells – and is sponsoring a scientific initiative with top academics to try to secure grant funding that will advance many clinical research programmes.